Novartis
Basel, Switzerland
East Hanover, New Jersey, United States
with other locations globally
United States
1932 articles with Novartis
-
Please check out the biopharma industry's COVID-19 stories that are trending for May 4, 2021.
-
BioSpace takes an in-depth look at the Top 25 of Q1.
-
Novartis Phase III BEOVU® data show potential for fluid resolution in more diabetic macular edema patients with fewer injections versus aflibercept
5/1/2021
Novartis is committed to bringing BEOVU 6 mg to DME patients and will submit data from KESTREL and KITE to global health authorities in H1 2021
-
Work-at-home arrangements created to respond to the COVID-19 pandemic have forced numerous companies in most sectors to reevaluate their work deals. This has also resulted in rethinking site locations and real estate needs. Here’s a look.
-
Novartis AG Chief Executive Officer Vas Narasimhan believes that the hybrid of remote and on-site office work is the future.
-
Executives at pharmaceutical companies are known for receiving large salaries. When bonuses and stock options are factored into the picture, their annual compensation can jump into the range of tens of millions of dollars, like Pfizer’s Albert Bourla, Alex Gorsky from Johnson & Johnson, and Astra...
-
AAN Annual Meeting Highlights: Sleep Quality, Migraine, COVID-19 Interferon Treatment and More
4/21/2021
The American Academy of Neurology Virtual Annual Meeting 2021 is ongoing from April 17 through 22, with literally hundreds of presentations. Here’s a peek at just some of them. -
The U.S. Food and Drug Administration (FDA) approved a prefilled syringe for self-injection of an allergic diseases treatment developed by Novartis and Genentech, a Roche company.
-
Artios Pharma Limited has entered into a global research collaboration with Novartis for the purpose of discovering and validating next-generation DDR targets and enhancing Novartis’ radioligand therapies.
-
Artios Pharma Announces Collaboration with Novartis to Create Next Generation DDR Cancer Therapies
4/7/2021
Artios eligible to receive up to $1.3 billion in discovery, development, regulatory and sales-based milestones in addition to royalty payments.
-
SOFIE affiliate, iTheranostics, executes agreement for its promising library of Fibroblast Activation Protein (FAP) targeted theranostics
3/30/2021
Novartis has acquired global development and commercial rights to therapeutic applications for iTheranostics' library of FAP-targeted drugs licensed from University of Heidelberg
-
In 2019, Novartis subsidiary AveXis announced it acquired a manufacturing facility in Colorado to provide additional production capacity for Zolgensma. Just two years later, the facility will be closed and 400 people will be without a job.
-
Targeted radioligand therapy 177Lu-PSMA-617 from Novartis significantly improved overall survival (OS) and radiographic progression-free survival (rPFS) in patients with PSMA-positive metastatic castration-resistant prostate cancer.
-
Clinical Catch-Up: March 15-19
3/22/2021
It was a relatively quiet week in terms of clinical trial news, but there were some significant releases. Here’s a look. -
New Company Debuts with $72 Million to Advance a Novel Class of Targeted Radiopharmaceuticals
3/18/2021
Aktis Oncology launched today with significant financing in hand to advance a novel class of targeted radiopharmaceuticals to treat a broad range of solid tumor cancers. The company’s launch was supported by pharma giants including Bristol Myers Squibb and Novartis. -
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
-
With more European countries pausing dosing of AstraZeneca’s COVID-19 vaccine over concerns about potential blood clotting side effects, Russia is seeking to fill in the gaps with its Sputnik V vaccine.
-
Molecular Partners and Novartis Announce Inclusion of COVID-19 Antiviral Candidate, ensovibep, in NIH-Sponsored ACTIV-3 Trial
3/15/2021
ACTIV-3 trial planned to investigate safety and efficacy of ensovibep in adults hospitalized with a COVID-19 diagnosis; first patient dose expected in Q2 2021
-
Clinical Catch-Up: March 8-12
3/15/2021
It was another busy week for clinical trial announcements. Here’s a look including trials for COVID-19, migraine, Parkinson's disease, Alzheimer's, HIV and more. -
The drug was being evaluated in 237 adults with locally advanced or metastatic non-small cell lung cancer whose disease progressed while on or after previous platinum-based chemotherapy and checkpoint inhibitor immunotherapy.